Radiation Oncology Section, Perugia General Hospital, Perugia, Italy.
Radiation Oncology Unit, Responsible Research Hospital, Campobasso, Italy.
Radiol Med. 2024 Sep;129(9):1329-1351. doi: 10.1007/s11547-024-01844-5. Epub 2024 Aug 28.
Multi-modal therapies for gynecological cancers management may determine a wide range of side effects which depend on therapy-related factors and patient characteristics and comorbidities. Curative or adjuvant pelvic radiotherapy is linked with acute and late toxicity due to irradiation of organs at risk, as small and large bowel, rectum, bladder, pelvic bone, vagina and bone marrow. Successful toxicity management varies with its severity, Radiation Centre practice and experience and skills of radiation oncologists. This position paper was designed by the Italian Association of Radiation and Clinical Oncology Gynecology Study Group to provide radiation oncologists with evidence-based strategies to prevent and manage acute and late toxicities and follow-up recommendations for gynecological cancer patients submitted radiotherapy. Six workgroups of radiation oncologists with over 5 years of experience in gynecologic cancers were setup to investigate radiotherapy-related toxicities. For each topic, PubMed database was searched for relevant English language papers from January 2005 to December 2022. Titles and abstracts of results were checked to verify suitability for the document. Reference lists of selected studies and review papers were added if pertinent. Data on incidence, etiopathogenesis, prevention, treatment and follow-up of acute and late side effects for each organ at risk are presented and discussed.
妇科癌症治疗的多模态疗法可能会产生广泛的副作用,这些副作用取决于治疗相关因素、患者特征和合并症。由于对危险器官(如小肠、大肠、直肠、膀胱、骨盆骨、阴道和骨髓)进行照射,根治性或辅助性盆腔放疗与急性和迟发性毒性有关。成功的毒性管理取决于其严重程度、放射治疗中心的实践经验和放射肿瘤学家的技能。本立场文件由意大利放射和临床肿瘤学协会妇科研究小组设计,旨在为放射肿瘤学家提供循证策略,以预防和管理急性和迟发性毒性,并为接受放射治疗的妇科癌症患者提供随访建议。成立了六个具有超过 5 年妇科癌症放射治疗经验的放射肿瘤学家工作组,以研究与放射治疗相关的毒性。对于每个主题,从 2005 年 1 月至 2022 年 12 月,在 PubMed 数据库中搜索了相关的英文论文。检查结果的标题和摘要以验证其是否适合该文件。如果相关,则添加选定研究和综述论文的参考文献列表。介绍和讨论了每个危险器官的急性和迟发性副作用的发生率、病因发病机制、预防、治疗和随访数据。